| The CD318/CD6 axis limits type 1 diabetes islet autoantigen-specific human T cell activation. | The CD318/CD6 axis limits type 1 diabetes islet autoantigen-specific human T cell activation.
Do JS, Arribas-Layton D, Juan J, Garcia I, Saraswathy S, Qi M, Montero E, Reijonen H. | 10/28/2024 |
| Myocardial Recovery in Recent Onset Dilated Cardiomyopathy: Role of CDCP1 and Cardiac Fibrosis. | Myocardial Recovery in Recent Onset Dilated Cardiomyopathy: Role of CDCP1 and Cardiac Fibrosis.
Liu D, Wang M, Murthy V, McNamara DM, Nguyen TTL, Philips TJ, Vyas H, Gao H, Sahni J, Starling RC, Cooper LT, Skime MK, Batzler A, Jenkins GD, Barlera S, Pileggi S, Mestroni L, Merlo M, Sinagra G, Pinet F, Krejčí J, Chaloupka A, Miller JD, de Groote P, Tschumperlin DJ, Weinshilboum RM, Pereira NL., Free PMC Article | 11/1/2023 |
| Metastatic prostate cancer-derived extracellular vesicles facilitate osteoclastogenesis by transferring the CDCP1 protein. | Metastatic prostate cancer-derived extracellular vesicles facilitate osteoclastogenesis by transferring the CDCP1 protein.
Urabe F, Kosaka N, Yamamoto Y, Ito K, Otsuka K, Soekmadji C, Egawa S, Kimura T, Ochiya T., Free PMC Article | 03/14/2023 |
| CDCP1 (CUB domain containing protein 1) is a potential urine-based biomarker in the diagnosis of low-grade urothelial carcinoma. | CDCP1 (CUB domain containing protein 1) is a potential urine-based biomarker in the diagnosis of low-grade urothelial carcinoma.
Liu CL, Tsai HW, Peng SL, Chang CP, Chang YH, Huang HS., Free PMC Article | 03/10/2023 |
| CDCP1 expression is frequently increased in aggressive urothelial carcinoma and promotes urothelial tumor progression. | CDCP1 expression is frequently increased in aggressive urothelial carcinoma and promotes urothelial tumor progression.
Saponaro M, Flottmann S, Eckstein M, Hommerding O, Klümper N, Corvino D, Hosni S, Schmidt A, Mönig N, Schmidt D, Ellinger J, Toma M, Kristiansen G, Bald T, Alimonti A, Ritter M, Hölzel M, Alajati A., Free PMC Article | 03/9/2023 |
| Evaluation of CDCP1 (CD318) and endoglin (CD105) expression as prognostic markers in acute myeloid leukemia. | Evaluation of CDCP1 (CD318) and endoglin (CD105) expression as prognostic markers in acute myeloid leukemia.
Ebian HF, Issa DR, Al-Karamany AS, Etewa RL, El Maghraby HM, Hussein S. | 06/11/2022 |
| CDCP1: A promising diagnostic biomarker and therapeutic target for human cancer. | CDCP1: A promising diagnostic biomarker and therapeutic target for human cancer.
Qi X, Gao J, Li Z, Zhang G, Li J, Fu Y, Cai M, Wang H, Tong T. | 06/11/2022 |
| SRC kinase activator CDCP1 promotes hepatocyte growth factor-induced cell migration/invasion of a subset of breast cancer cells. | SRC kinase activator CDCP1 promotes hepatocyte growth factor-induced cell migration/invasion of a subset of breast cancer cells.
Kawase N, Sugihara A, Kajiwara K, Hiroshima M, Akamatsu K, Nada S, Matsumoto K, Ueda M, Okada M., Free PMC Article | 04/30/2022 |
| Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers. | Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers.
Lim SA, Zhou J, Martinko AJ, Wang YH, Filippova EV, Steri V, Wang D, Remesh SG, Liu J, Hann B, Kossiakoff AA, Evans MJ, Leung KK, Wells JA., Free PMC Article | 04/2/2022 |
| Preclinical Molecular PET-CT Imaging Targeting CDCP1 in Colorectal Cancer. | Preclinical Molecular PET-CT Imaging Targeting CDCP1 in Colorectal Cancer.
Cuda TJ, He Y, Kryza T, Khan T, Tse BW, Sokolowski KA, Liu C, Lyons N, Gough M, Snell CE, Wyld DK, Rose S, Riddell AD, Stevenson ARL, Thomas PA, Clark DA, Puttick S, Hooper JD., Free PMC Article | 02/26/2022 |
| Prospective Identification of Elevated Circulating CDCP1 in Patients Years before Onset of Lung Cancer. | Prospective Identification of Elevated Circulating CDCP1 in Patients Years before Onset of Lung Cancer.
Dagnino S, Bodinier B, Guida F, Smith-Byrne K, Petrovic D, Whitaker MD, Haugdahl Nøst T, Agnoli C, Palli D, Sacerdote C, Panico S, Tumino R, Schulze MB, Johansson M, Keski-Rahkonen P, Scalbert A, Vineis P, Johansson M, Sandanger TM, Vermeulen RCH, Chadeau-Hyam M., Free PMC Article | 12/18/2021 |
| Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer-Letter. | Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer-Letter.
Birnbaum DJ, Finetti P, Birnbaum D, Bertucci F. | 11/27/2021 |
| Substrate-biased activity-based probes identify proteases that cleave receptor CDCP1. | Substrate-biased activity-based probes identify proteases that cleave receptor CDCP1.
Kryza T, Khan T, Lovell S, Harrington BS, Yin J, Porazinski S, Pajic M, Koistinen H, Rantala JK, Dreyer T, Magdolen V, Reuning U, He Y, Tate EW, Hooper JD. | 09/11/2021 |
| Programmable N6-methyladenosine modification of CDCP1 mRNA by RCas9-methyltransferase like 3 conjugates promotes bladder cancer development. | Programmable N6-methyladenosine modification of CDCP1 mRNA by RCas9-methyltransferase like 3 conjugates promotes bladder cancer development.
Ying X, Jiang X, Zhang H, Liu B, Huang Y, Zhu X, Qi D, Yuan G, Luo J, Ji W., Free PMC Article | 08/28/2021 |
| Effective targeting of intact and proteolysed CDCP1 for imaging and treatment of pancreatic ductal adenocarcinoma. | Effective targeting of intact and proteolysed CDCP1 for imaging and treatment of pancreatic ductal adenocarcinoma.
Kryza T, Khan T, Puttick S, Li C, Sokolowski KA, Tse BW, Cuda T, Lyons N, Gough M, Yin J, Parkin A, Deryugina EI, Quigley JP, Law RHP, Whisstock JC, Riddell AD, Barbour AP, Wyld DK, Thomas PA, Rose S, Snell CE, Pajic M, He Y, Hooper JD., Free PMC Article | 05/22/2021 |
| The emerging role of the MiR-1272-ADAM9-CDCP1 signaling pathway in the progression of glioma. | The emerging role of the MiR-1272-ADAM9-CDCP1 signaling pathway in the progression of glioma.
Geng F, Lu GF, Luo YJ, Dominguez S, Kong DY, Shen LH, Luo XM, Yang X, Hu M, Lai WS, Jiang ZS, Chen YS., Free PMC Article | 05/15/2021 |
| Increased Plasma Levels of the Co-stimulatory Proteins CDCP1 and SLAMF1 in Patients With Autoimmune Endocrine Diseases. | Increased Plasma Levels of the Co-stimulatory Proteins CDCP1 and SLAMF1 in Patients With Autoimmune Endocrine Diseases.
Magnusson L, Espes D, Casas R, Carlsson PO., Free PMC Article | 04/24/2021 |
| Identification of CD318, TSPAN8 and CD66c as target candidates for CAR T cell based immunotherapy of pancreatic adenocarcinoma. | Identification of CD318, TSPAN8 and CD66c as target candidates for CAR T cell based immunotherapy of pancreatic adenocarcinoma.
Schäfer D, Tomiuk S, Küster LN, Rawashdeh WA, Henze J, Tischler-Höhle G, Agorku DJ, Brauner J, Linnartz C, Lock D, Kaiser A, Herbel C, Eckardt D, Lamorte M, Lenhard D, Schüler J, Ströbel P, Missbach-Guentner J, Pinkert-Leetsch D, Alves F, Bosio A, Hardt O., Free PMC Article | 03/20/2021 |
| CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo. | CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo.
Alajati A, D'Ambrosio M, Troiani M, Mosole S, Pellegrini L, Chen J, Revandkar A, Bolis M, Theurillat JP, Guccini I, Losa M, Calcinotto A, De Bernardis G, Pasquini E, D'Antuono R, Sharp A, Figueiredo I, Nava Rodrigues D, Welti J, Gil V, Yuan W, Vlajnic T, Bubendorf L, Chiorino G, Gnetti L, Torrano V, Carracedo A, Camplese L, Hirabayashi S, Canato E, Pasut G, Montopoli M, Rüschoff JH, Wild P, Moch H, De Bono J, Alimonti A., Free PMC Article | 02/2/2021 |
| Effect of NLK on the proliferation and invasion of laryngeal carcinoma cells by regulating CDCP1. | Effect of NLK on the proliferation and invasion of laryngeal carcinoma cells by regulating CDCP1.
Shen N, Duan XH, Wang XL, Yang QY, Feng Y, Zhang JX. | 10/3/2020 |
| CD318 expression may serve as novel prognostic factor depending on implemented therapy in acute myeloid leukemia patients | Identification of CD318 (CDCP1) as novel prognostic marker in AML.
Heitmann JS, Hagelstein I, Hinterleitner C, Roerden M, Jung G, Salih HR, Märklin M, Kauer J., Free PMC Article | 05/16/2020 |
| Detailed cell fractionation, immunoprecipitation, microscopy, and immunohistochemical analyses demonstrated that CDCP1 promotes translocation of the key regulators of Wnt signaling, b-catenin, and E-cadherin, to the nucleus. Of functional importance, disruption of CDCP1 reduces nuclear localized, chromatin-associated b-catenin and nuclear localized E-cadherin, increases sequestration of these proteins in cell membranes | CDCP1 enhances Wnt signaling in colorectal cancer promoting nuclear localization of β-catenin and E-cadherin.
He Y, Davies CM, Harrington BS, Hellmers L, Sheng Y, Broomfield A, McGann T, Bastick K, Zhong L, Wu A, Maresh G, McChesney S, Yau Wong K, Adams MN, Sullivan RC, Palmer JS, Burke LJ, Ewing AD, Zhang X, Margolin D, Li L, Lourie R, Matsika A, Srinivasan B, McGuckin MA, Lumley JW, Hooper JD. | 04/25/2020 |
| The CDCP1 is cleaved by serine proteases at adjacent sites, arginine 368 (R368) and lysine 369 (K369), which induces cell migration in vitro and metastasis in vivo. | Evidence that cell surface localization of serine protease activity facilitates cleavage of the protease activated receptor CDCP1.
He Y, Reid JC, He H, Harrington BS, Finlayson B, Khan T, Hooper JD. | 05/18/2019 |
| CDCP1 was the most significant (FDR adjusted p-value 0.006). Correlation with CDCP1 concentration was most significant for CD34+ concentration and nucleated cell count. Multivariate analysis showed that CD34 and gender seemed to influence the level of CDCP1. | Concentration of the CDCP1 protein in human cord plasma may serve as a predictor of hematopoietic stem and progenitor cell content.
Frändberg S, Asp J, Waldner B, Holgersson J, Palmqvist L. | 03/23/2019 |
| Study discovered a new mechanism of regulation of CDK5 through loss of CDCP1, which dynamically regulates beta1-integrin in non-adherent cells and which may promote vascular dissemination in patients with advanced prostate cancer. | Regulation of inside-out β1-integrin activation by CDCP1.
Pollan SG, Huang F, Sperger JM, Lang JM, Morrissey C, Cress AE, Chu CY, Bhowmick NA, You S, Freeman MR, Spassov DS, Moasser MM, Carter WG, Satapathy SR, Shah K, Knudsen BS., Free PMC Article | 03/2/2019 |